MXCT
NASD MaxCyte, Inc.$1.45 ↓ -0.02 (-1.36%) Trading Down from the previous close of $1.47, $0.08 below the day’s high of $1.53
- YTD change
- -6.45%
- vs 20-day SMA
- +26.37%
- vs 200-day SMA
- +37.06%
Price ranges
Price & Performance
+0.56 (+64.33%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 91.7% away from all-time highs of $17.44
- MXCT is down 6% since the beginning of the year
- MXCT is down 15% over the past 12 months
- MXCT is up 17% over the past 1 month
- 1% of all MXCT investors are betting against MXCT
MXCT reads very good: price sits above both the 20- and 200-day averages, the 12-month move is -16.4%.
- Previous minute
- +$0.00
- Last hour
- -$0.02
- Last 5 days
- +50.37%
- vs 8-day SMA
- +21.48%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.